UroGen
在场
高管
查看带有其 16 名主要高管的组织结构图
UroGen 搜索最多的简介
- Elizabeth Barrett, Director, President and Chief Executive Officer
- Fred Cohen, Director
- Cynthia Butitta, Director
高管在UroGen变化
- Don Kim, Chief Financial Officer, 已经离开公司 (新闻发布的2024十月11号).
- Chris Degnan已作为Chief Financial Officer加入公司 (新闻发布的2024十月11号).
- David Lin已作为Chief Commercial Officer加入公司 (新闻发布的2024六月4号).
创建提醒
跟踪 UroGen 的高管变动
生物技术
UroGen 拥有 2,330 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Nuvig Therapeutics 刚刚宣布为 161 筹款数百万美元。 (公布2024十二月5号).
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
UroGen 的最新新闻稿
- UroGen Pharma to Present at Upcoming Investor Conferences | Urogen Pharma Inc.
- News Releases | Urogen Pharma Inc.
- News Releases | Urogen Pharma Inc.
- The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Urogen Pharma Inc.
- UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments | Urogen Pharma Inc.
- News Releases | Urogen Pharma Inc.
- UroGen Announces $120 Million Private Placement of Ordinary Shares | Urogen Pharma Inc.
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Urogen Pharma Inc.
- UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials | Urogen Pharma Inc.
- UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 | Urogen Pharma Inc.
- View more press releases Close
通过电子邮件
